Drug Profile
Research programme: inflammation therapeutics - Jexys
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Jexys Pharmaceuticals
- Class
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in Israel
- 16 Dec 2008 Early research in Inflammation in Israel (unspecified route)